Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.
作者信息
Uriu Keiya, Ito Jumpei, Zahradnik Jiri, Fujita Shigeru, Kosugi Yusuke, Schreiber Gideon, Sato Kei
机构信息
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
出版信息
Lancet Infect Dis. 2023 Mar;23(3):280-281. doi: 10.1016/S1473-3099(23)00051-8. Epub 2023 Jan 31.
Abstract
摘要
相似文献
1
Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.
Lancet Infect Dis. 2023 Mar;23(3):280-281. doi: 10.1016/S1473-3099(23)00051-8. Epub 2023 Jan 31.
2
XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2.
Microbiol Res. 2023 May;270:127337. doi: 10.1016/j.micres.2023.127337. Epub 2023 Feb 15.
3
Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.
Microbiol Spectr. 2024 Mar 5;12(3):e0383123. doi: 10.1128/spectrum.03831-23. Epub 2024 Feb 5.
4
Applications of peptide-functionalized or unfunctionalized selenium nanoparticles for the passivation of SARS-CoV-2 variants and the respiratory syncytial virus (RSV).
Colloids Surf B Biointerfaces. 2024 Jan;233:113638. doi: 10.1016/j.colsurfb.2023.113638. Epub 2023 Nov 9.
5
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Lancet Infect Dis. 2023 Jul;23(7):799-805. doi: 10.1016/S1473-3099(23)00060-9. Epub 2023 Mar 13.
6
Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
Cell Rep. 2023 Dec 26;42(12):113580. doi: 10.1016/j.celrep.2023.113580. Epub 2023 Dec 15.
7
8
Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
Med Sci Monit. 2023 Feb 1;29:e939580. doi: 10.12659/MSM.939580.
9
Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
Cell. 2024 Feb 1;187(3):585-595.e6. doi: 10.1016/j.cell.2023.12.026. Epub 2024 Jan 8.
10
SARS-CoV-2 Omicron variant: recent progress and future perspectives.
Signal Transduct Target Ther. 2022 Apr 28;7(1):141. doi: 10.1038/s41392-022-00997-x.
引用本文的文献
1
Monitoring SARS-CoV-2 Dissemination in Wastewater and Virus Isolation in Cell Cultures: An Integrated Approach for Pathogen Detection and Surveillance.
J Cell Mol Med. 2025 Sep;29(17):e70805. doi: 10.1111/jcmm.70805.
2
SARS-CoV-2 secondary attack rates and risks for transmission among agricultural workers and their households in Guatemala, 2022-2023.
IJID Reg. 2025 May 27;16:100676. doi: 10.1016/j.ijregi.2025.100676. eCollection 2025 Sep.
3
An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant.
EBioMedicine. 2025 Jun 6;117:105794. doi: 10.1016/j.ebiom.2025.105794.
4
A protein language model for exploring viral fitness landscapes.
Nat Commun. 2025 May 13;16(1):4236. doi: 10.1038/s41467-025-59422-w.
5
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.
Vaccines (Basel). 2025 Apr 17;13(4):424. doi: 10.3390/vaccines13040424.
6
SARS-CoV-2 spike protein: structure, viral entry and variants.
Nat Rev Microbiol. 2025 May 6. doi: 10.1038/s41579-025-01185-8.
7
Genome data artifacts and functional studies of deletion repair in the BA.1 SARS-CoV-2 spike protein.
Virus Evol. 2025 Mar 11;11(1):veaf015. doi: 10.1093/ve/veaf015. eCollection 2025.
8
Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants.
PLoS Pathog. 2025 Apr 11;21(4):e1013034. doi: 10.1371/journal.ppat.1013034. eCollection 2025 Apr.
9
Using a multi-strain infectious disease model with physical information neural networks to study the time dependence of SARS-CoV-2 variants of concern.
PLoS Comput Biol. 2025 Feb 14;21(2):e1012778. doi: 10.1371/journal.pcbi.1012778. eCollection 2025 Feb.
10
Uncovering the Binding Mechanism of Mutated Omicron Variants via Computational Strategies.
ACS Omega. 2025 Jan 13;10(3):2790-2798. doi: 10.1021/acsomega.4c08562. eCollection 2025 Jan 28.
本文引用的文献
1
Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
Nat Commun. 2023 May 16;14(1):2800. doi: 10.1038/s41467-023-38435-3.
2
Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant.
Nat Commun. 2023 May 11;14(1):2671. doi: 10.1038/s41467-023-38188-z.
3
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
Lancet Infect Dis. 2023 Mar;23(3):278-280. doi: 10.1016/S1473-3099(23)00010-5. Epub 2023 Feb 3.
4
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.
Cell Host Microbe. 2022 Nov 9;30(11):1540-1555.e15. doi: 10.1016/j.chom.2022.10.003. Epub 2022 Oct 18.
5
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
Cell. 2022 Oct 13;185(21):3992-4007.e16. doi: 10.1016/j.cell.2022.09.018. Epub 2022 Sep 14.
6
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9.
7
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
Cell. 2022 Jun 9;185(12):2103-2115.e19. doi: 10.1016/j.cell.2022.04.035. Epub 2022 May 2.
Zotero 插件